5 of Last Week's Biggest Winners

These five stocks posted double-digit percentage gains.

Jun 29, 2014 at 1:00PM

It was a mixed week on Wall Street, with the Nasdaq moving higher and the Dow moving lower, but there were plenty of stocks really making some serious moves. Let's take a closer look at five of this past week's biggest scorchers.

Company

June 27

Weekly Gain

Vertex Pharmaceuticals (NASDAQ:VRTX)

$93.77

44%

Glu Mobile (NASDAQ:GLUU)

$4.67

19%

Organovo Holdings (NYSEMKT:ONVO)

$8.60

18%

Inovio Pharmaceuticals (NASDAQ:INO)

$10.73

17%

3D Systems (NYSE:DDD)

$59.07

11%

Source: Barron's.

Let's start with Vertex Pharmaceuticals. The biotech soared on positive studies showing the effectiveness of combining two of its drugs for the treatment of patients with cystic fibrosis who also happen to have two copies of a rare genetic mutation. It may be a thin market to treat, but the likely high price of the combination could generate billions in revenue for Vertex if it's successful on the market. 

Glu Mobile moved higher after announcing developer support for the new Android TV platform that will take mobile games to the larger television screen. Android-based gaming consoles have gotten off to a slow start, but now the search giant behind the open-source operating system itself is throwing its weight behind the console gaming market. 

Two of Glu Mobile's biggest games -- Deer Hunter 2014 and Eternity Warriors 2 -- are now optimized for the larger screen experience. Earlier in the week, Glu Mobile also rolled out Kim Kardashian: Hollywood for iOS and Android. The game features the most popular Kardashian as she guides players in their quest to succeed in Tinseltown.

Organovo Holdings showed a healthy pulse after Roche's head of mechanistic safety offered up an encouraging opinion of Organovo's 3-D liver assay test at the 3D Cell Culture 2014 conference. His findings show that the test is able to distinguish between toxic and non-toxic compounds that are chemically similar. It's an encouraging third-party endorsement, and Organovo reiterated its goal to launch the 3-D liver assay test later this year. 

Inovio Pharmaceuticals was another winner. It started out the week announcing that it was initiating a clinical trial for its DNA immunotherapy product -- INO-3112 -- in treating HPV-associated cervical cancer. Biotech investors know that the clinical trial process is long and often ends in heartbreak, but the approval process for potentially promising drugs has to start somewhere. 

3D Systems also popped out in a terrific week for 3-D printing stocks where all three of the most actively traded players in this promising niche experienced double-digit percentage share gains. The week got off to a strong start on momentum from the prior week, wrapping up with Jefferies' issuance of a positive note on the booming growth prospects of industrial prototype creation. 3D Systems also introduced the iSense scanner for the iPad, turning the tablet into a mobile physical photography camera that plays nicely with its 3-D printer.

3D Systems has still taken a beating in 2014. The poster child for 3-D printing is trading 36% lower year to date. However, the stock has also showed signs of turning the corner, climbing 36% since bottoming out in April.

Leaked: This coming consumer device can change everything
Imagine the multibillion-dollar sales potential behind a product that can revolutionize the way the world shops and interacts with its favorite brands every day. Now picture one small, under-the radar company at the epicenter of this revolution that makes this all possible. And its stock price has nearly an unlimited runway ahead for early, in-the-know investors. To be one of them and hop aboard this stock before it takes off, just click here.  

Rick Munarriz has no position in any stocks mentioned. The Motley Fool recommends 3D Systems and Vertex Pharmaceuticals and owns shares of 3D Systems. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers